SAT0485 Safety Profile of the IL-1 Receptor Antagonist Kineret® (Anakinra) in a Long-Term Outcome Study in Patients with Severe Cryopyrin-Associated Periodic Syndromes (Caps)

T Kullenberg,M Löfqvist,N Plass,C Sibley,H Olivecrona,B Kost,R Goldbach-Mansky

doi:10.1136/annrheumdis-2013-eular.2209

SAT0485 Safety Profile of the IL-1 Receptor Antagonist Kineret® (Anakinra) in a Long-Term Outcome Study in Patients with Severe Cryopyrin-Associated Periodic Syndromes (Caps)

T Kullenberg, M Löfqvist + Show 5 more

https://doi.org/10.1136/annrheumdis-2013-eular.2209

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2013

Affiliation: Swedish Orphan Biovitrum (Sweden), National Institute of Arthritis and Musculoskeletal and Skin Diseases

#Swedish Orphan Biovitrum AB #Upper Respiratory Tract Infections + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

BackgroundInterleukin-1 (IL-1) is a potent mediator of of inflammation. Kineret is a recombinant, non-glycosylated form of the human IL-1 receptor antagonist (IL-1Ra). The safety profile of Kineret is well documented...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.